Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

Primary Visceral Leishmaniasis Clinical Trial

Official title:
A Phase II Randomized, Parallel Arm, Open-labeled Clinical Trial to Assess the Safety and Efficacy of the Combination of Sodium Stibogluconate Plus Single Dose AmBisome®, Miltefosine Plus Single Dose AmBisome® and Miltefosine Alone for the Treatment of Primary Visceral Leishmaniasis in Eastern Africa

Status Completed

Clinical Trial Summary

This study is to assess if shorter combinations of SSG plus single dose AmBisome®, Miltefosine plus single dose AmBisome® and Miltefosine alone are effective in treating visceral leishmaniasis in Eastern Africa.

Clinical Trial Description

The current study intends to look at potential feasible short course combination therapies as well as evaluate (and possibly register) miltefosine in its conventional dose against VL in Sudan and Kenya. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01067443
Study type	Interventional
Source	Drugs for Neglected Diseases
Contact
Status	Completed
Phase	Phase 2
Start date	March 2010
Completion date	June 2011

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05593666` - A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis	Phase 2
	Recruiting	`NCT05957978` - LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study	Phase 2